[Resecting hematogenous metastases: reasons against].
Urological malignancies represent approximately 40% of all solid tumors. Synchronous or metachronous organ metastases develop in 30% of patients. Depending on the tumor entity and tumor characteristics, resection of metastases can improve patient survival. Surgical resection of residual tumors is an integral part of the multimodal therapy concept of patients with nonseminomatous metastatic germ-cell cancer. Surgical inoperability is the only reason not to resect. Resection of hematogenous metastases from renal cell carcinoma has been postulated as a standard therapy for decades. Appropriate patient selection is the key for a survival benefit. Prognosticators such as patient's general condition as well as number, location, and size of metastases help to counsel and select patients accordingly. Metastases of transitional cell or penile carcinoma should only be resected when a response to systemic treatment is evident in the individual case. There is no evidence in favor of resecting organ-metastases of prostate cancer in the current guidelines and the literature. In this article, arguments against resection of metastases following the current literature and guidelines are described.
Urologische Klinik und Poliklinik, Universitätsmedizin, Johannes Gutenberg Universität Mainz, Langenbeckstraße 1, 55131, Mainz, Deutschland, frederik.roos@unimedizin-mainz.de.
F C
FC
Roos
J W
JW
Thüroff
D002292:Carcinoma, Renal Cell / Q000473:pathology / Q000556:secondary* / Q000601:surgery*; D002295:Carcinoma, Transitional Cell / Q000473:pathology / Q000556:secondary* / Q000601:surgery*; D019317:Evidence-Based Medicine; D006801:Humans; D008207:Lymphatic Metastasis; D009360:Neoplastic Cells, Circulating / Q000473:pathology*; D017410:Practice Guidelines as Topic; D011379:Prognosis; D016896:Treatment Outcome; D014571:Urologic Neoplasms / Q000473:pathology* / Q000601:surgery*